Dr. Massimo Cristofanilli, MD
Claim this profileNorthwestern University
Studies Breast Cancer
Studies Breast cancer
3 reported clinical trials
10 drugs studied
Area of expertise
1Breast Cancer
Stage IV
HER2 positive
HER2 negative
2Breast Cancer
HER2 positive
Stage II
Stage III
Affiliated Hospitals
Northwestern University
NYP/Weill Cornell Medical Center
Clinical Trials Massimo Cristofanilli, MD is currently running
Chemotherapy Reduction After Surgery
for Breast Cancer
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
Recruiting1 award Phase 227 criteria
Vaccine + Chemotherapy + Immunotherapy
for Breast Cancer
This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine) works in treating patients with triple negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. It is not yet known whether giving nab-paclitaxel, durvalumab, and tremelimumab with or without neoantigen vaccine will work better in treating patients with triple negative breast cancer.
Recruiting1 award Phase 222 criteria
More about Massimo Cristofanilli, MD
Clinical Trial Related4 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Massimo Cristofanilli, MD has experience with
- Palbociclib
- Avelumab
- Fulvestrant
- Trastuzumab
- Pertuzumab
- Paclitaxel
Breakdown of trials Massimo Cristofanilli, MD has run
Breast Cancer
Breast cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Massimo Cristofanilli, MD specialize in?
Massimo Cristofanilli, MD focuses on Breast Cancer and Breast cancer. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are HER2 positive.
Is Massimo Cristofanilli, MD currently recruiting for clinical trials?
Yes, Massimo Cristofanilli, MD is currently recruiting for 2 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Massimo Cristofanilli, MD has studied deeply?
Yes, Massimo Cristofanilli, MD has studied treatments such as Palbociclib, Avelumab, Fulvestrant.
What is the best way to schedule an appointment with Massimo Cristofanilli, MD?
Apply for one of the trials that Massimo Cristofanilli, MD is conducting.
What is the office address of Massimo Cristofanilli, MD?
The office of Massimo Cristofanilli, MD is located at: Northwestern University, Chicago, Illinois 60611 United States. This is the address for their practice at the Northwestern University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.